Chow, W.A., Valdes-Albini, F., and Guo, S. Nelfinavir Induces Liposarcoma Apoptosis and Cell-Cycle Arrest by Upregulating SREBP-1. Manuscript submitted for publication, 2006.
Chow, W.A., Bedell, V., Borden E., Goldblum J., Hicks D., and Slovak M. Methylthioadenosine Phosphorylase Gene Deletions are Frequently Detected by Fluorescence-in-situ Hybridization in Conventional Chondrosarcomas. Cancer Genet Cyto. In press, 2006.
Chow W.A., Synold TW, Tetef ML, Longmate J, Frankel P, Lawrence J, Al-Kadhimi Z, Leong L, Lim D, Margolin K, Morgan RJ Jr, Raschko J, Shibata S, Somlo G, Twardowski P, Yen Y, Doroshow JH. Feasibility study of concurrent infusional dexrazoxane and dose-intensive doxorubicin administered over 96 hours in the treatment of advanced malignancies. Cancer Chemother. Pharmacol. 54: 241-248, 2004.
Valdes, F., and Chow, W.A. The HIV Protease Inhibitor Nelfinavir Inhibits Human SW872 Liposarcoma Clonogenicity by Inducing Apoptosis and is Associated with an Increase in Levels of SREBP-1. Proc. Amer. Assoc. Cancer Res. 44: 1752a, 2004.
Morgan RJ, Doroshow JH, Synold T, Lim D, Shibata S, Margolin K, Schwarz R, Leong L, Somlo G, Twardowski P, Yen Y, Chow W.A., Lin P, Paz B, Chu D, Frankel P, Stalter S. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the the peritoneal cavity: Dose-limiting toxicity and pharmacokinetics. Clin. Cancer Res. 9: 5896-5901, 2003.
Morgan RJ, Newman EM, Sowers L, Scanlon K, Harrison J, Akman S, Leong L, Margolin K, Niland J, Raschko J, Somlo G, Carroll M, Chow W.A., Tetef M, Hamasaki V, Yen Y, Doroshow JH. Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies. Cancer Chemother. Pharmacol. 51: 459-464, 2003.
Somlo G, Simpson JF, Frankel P, Chow W.A., Leong L, Margolin K, Morgan R, Jr., Raschko J, Shibata S, Forman S, Kogut N, McNamara M, Molina A, Somlo E, Doroshow JH. Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer. Brit. J. Cancer. 87: 281-288, 2002.
Yen Y, Chow W.A., Leong L, Margolin K, Morgan R, Raschko J, Shibata S, Somlo G, Twardowski P, Frankel P, Longmate J, Synold T, Newman EM, Lenz HJ, Gandara D, Doroshow JH. Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial. Cancer Chemo. Pharm. 50: 353-359, 2002.
Somlo G, Doroshow JH, Ahn C, Chow W.A., Hamasaki V, Leong L, Margolin K, Morgan R, Raschko J, Shibata S, O’Donnell M, Smith E, Tetef M, Forman S, Yen Y, Molina A, Sniecinski I. Tandem cycle of high-dose melphalan and cisplatin with peripheral stem cell rescue in patients with breast cancer and other malignancies. Biol. Blood Marrow Transplant. 7: 284-293, 2001.
Morgan RJ, Doroshow JH, Leong L, Schriber J, Shibata S, Forman S, Hamasaki V, Margolin K, Somlo G, Alvarnas J, McNamara M, Longmate J, Raschko J, Chow W.A., Vasilev S, McGonigle K, Yen Y. Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer. Bone Marrow Transplant. 28: 859-863, 2001.
Tetef ML, Synold TW, Chow W.A., Leong L, Margolin K, Morgan R, Raschko J, Shibata S, Somlo S, Yen Y, Groshen S, Johnson K, Lenz H-J, Gandara D, and Doroshow JH. Phase I trial of ninety-six hour continuous infusion of dexrazoxane in patients with advanced malignancies. Clin. Cancer Res. 7: 1569-1576, 2001.
Somlo G, Doroshow JH, Ahn C, Chow W.A., Hamasaki V, Leong L, Margolin K, Morgan R, Raschko J, Shibata S, O'Donnell M, Smith E, Tetef M, Forman S, Yen Y, Molina A, Snieicinski I. Tandem cycle of high-dose melphalan and cisplatin with peripheral stem cell rescue in patients with breast cancer and other malignancies. Biol. Blood Marrow Transplant. 7: 284-293, 2001.
Morgan RJ, Jr., Synold T, Carr BI, Doroshow JH, Womack EP, Shibata S, Somlo G, Raschko J, Leong L, McNamara M, Chow W.A., Tetef M, Margolin K, Akman S, Longmate J. Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy. Cancer Chemo Pharmacol. 47: 327-332, 2001.
Chow W.A., Fang JJ, Yee J-K. The interferon regulatory factor family participate in regulation of Fas ligand gene expression in T cells. J. Immunol. 164: 3512-3518, 2000.
Raschko JW, Synold TW, Chow W.A., Coluzzi P, Hamasaki V, Leong LA, Margolin KA, Morgan RJ, Shibata SI, Somlo G, Tetef ML, Yen Y, ter Veer A, Doroshow JH. A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A. Cancer Chemo Pharm. 46: 403-410, 2000.
Tetef M, Leong L, Ahn c, Akman S, Chow W.A., Margolin K, Morgan RJ Jr., Raschko J, Shibata S, Somlo G, Doroshow JH. Cisplatin and infusional cytosine arabinoside for the treatment of gastrointestinal carcinomas and adenocarcinoma of unknown primary origin: a phase II trial. Cancer Invest. 7: 114-117, 1999.
Schwarz RE, Chow W.A., Andersen JS, Arber DA, Balch CM. Soft tissue masses of the chest wall and axilla: has metastatic melanoma been considered? Am J Clin Oncol. 22: 174-177, 1999.
Castanotto D, Chow W.A., Li H, Rossi JJ. Unusual interactions between cleavage products of a cis-cleaving hammerhead ribozyme. Antisense & Nucleic Acid Drug Dev. 8: 499-506, 1998.
Castanotto D, Li H, Chow W.A., Rossi JJ, Deshler JO. Structural similarities between hammerhead ribozymes and the spliceosomal RNAs could be responsible for lack of ribozyme cleavage in yeast. Antisense Nucl Acid Drug Dev.8:1, 1998.
Somlo G, Doroshow JH, Forman SJ, Odom-Maryon T, Lee J, Chow W.A., Hamasaki V, Leong L, Morgan R Jr, Margolin K, Raschko J, Shibata S, Tetef M, Yen Y, Simpson J, Molina A. High-dose chemotherapy and stem-cell rescue in the treatment of high- risk breast cancer: prognostic indicators of progression-free and overall survival. J Clin Oncol. 15:2882-2893, 1997.
Newman EM, Carroll M, Akman SA, Chow W.A., Coluzzi P, Hamasaki V, Leong LA, Margolin KA, Morgan RJ, Raschko JW, Shibata S, Somlo G, Tetef M, Yen Y, Ahn CW, Doroshow JH. . Pharmacokinetics and toxicity of 120-hour continuous infusion hydroxyurea in patients with advanced solid tumors. Cancer Chemother Pharmacol. 39:254-258, 1997.
Somlo G, Doroshow JH, Lev-Ran A, Hwang DL, Ahn C, Forman SJ, Raschko JW, Margolin KA, Morgan RJ, Leong A, Hamasaki VK, Chow W.A., Molina A, Ahmad B, Akman SA. Effect of low-dose prophylactic dopamine on high dose cisplatin-induced electrolyte wasting, ototoxicity and epidermal growth factor excretion: a randomized, placebo-controlled double-blind trial. J Clin Oncol. 13:1231-1237, 1995
Tetef M, Margolin K, Ahn C, Akman S, Chow W.A., Coluzzi P, Hamasaki V, Leong L, Morgan RJ, Raschko J, Shibata S, Somlo G, Yen Y, Doroshow JH. Mitomycin C and menadione for the treatment of lung cancer: a phase II trial. Invest New Drugs. 13:157-162, 1995.
This is a partial list. Full publications list available upon request. Information on this page may be self-reported and is subject to change at any time. Last updated: 03/06.